Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) Gets Downgraded


Dallas, Texas 12/25/2013 (FINANCIALSTRENDS) – Thomson Reuters/Verus’ equity researchers downgraded Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) from a “hold” to a “sell” rating on Tuesday. Recently, numerous other equities-research analysts have weighed on the Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) stock. On 6 Friday, Merrill Lynch analysts assigned an “underperform” rating on the company stock. Bank of America Corp analysts initiated coverage on Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) shares on Friday, 6 December and have assigned an “underperform” rating on the stock with a PT of $1.50.

Gabelli analysts reiterated their “buy” rating on Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) shares on Friday, 11 October. Four research-analysts have assigned a “sell” rating on the Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) stock, and 2have have assigned a “buy” rating. Currently, the average rating on the Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) stock is a “Hold” and the average PT is $2.17.

Tuesday’s trading

In the trading session on Tuesday there was a drop of 1.05% in Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX). The shares opened at $1.91 climbed to an intraday high of $1.94 and closed at $1.89. Close to 0.497M shares were traded on Tuesday and the average volume of 1.35M shares got traded over a period of 30 days. The 52-week low of Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) shares is $1.70 while the 52-week high stands at $3.18. The company has a market capitalization of $970.55 million.                        

About the company

Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) is a bio-pharma company that is focused on discovering and developing breakthrough treatments for different human diseases. The company uses its gene-knockout technologies & an integrated platform of its medical technologies to study physiological & behavioral functions of approximately 5,000 genes in mice & assessed utility of proteins that are encoded by the corresponding human- genes as the drug targets. It has 5 drug programs in different stages of clinical-development and advanced small-molecule compounds from numerous additional drug programs in various stages of pre-clinical development &research.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.